{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:43:17Z","timestamp":1785714197329,"version":"3.56.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,29]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Genomic deletions of CDKN2A\/2B are a new independent prognostic risk factor in adult Ph+ ALL.<\/jats:p>","DOI":"10.1182\/blood-2017-07-796862","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T21:55:36Z","timestamp":1516312536000},"page":"1464-1475","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":74,"title":["Genomic CDKN2A\/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation"],"prefix":"10.1182","volume":"131","author":[{"given":"Heike","family":"Pfeifer","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Raum","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"},{"name":"Department of Pediatrics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Markovic","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Fey","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Obl\u00e4nder","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovita","family":"Pressler","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Wunderle","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Mainz, Mainz, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital M\u00fcnster, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Goekbuget","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-1330","authenticated-orcid":false,"given":"Oliver G.","family":"Ottmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany;"},{"name":"Division of Cancer and Genetics, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2019111907022883700_B1","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","article-title":"Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00","volume":"28","author":"Bassan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111907022883700_B2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2019111907022883700_B3","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111907022883700_B4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"1","key":"2019111907022883700_B5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2009.011221","article-title":"Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial","volume":"95","author":"Ribera","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"2019111907022883700_B6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2019111907022883700_B7","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"issue":"24","key":"2019111907022883700_B8","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111907022883700_B9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/leu.2010.228","article-title":"Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia","volume":"25","author":"Mizuta","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"2019111907022883700_B10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2019111907022883700_B11","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3892\/ijo_00000290","article-title":"Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia","volume":"34","author":"Kawamata","year":"2009","journal-title":"Int J Oncol"},{"issue":"31","key":"2019111907022883700_B12","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111907022883700_B13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2009.18","article-title":"Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions","volume":"23","author":"Mullighan","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2019111907022883700_B14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111907022883700_B15","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3324\/haematol.2009.011114","article-title":"Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia","volume":"95","author":"Okamoto","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111907022883700_B16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.056135","article-title":"IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol","volume":"98","author":"D\u00f6rge","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"2019111907022883700_B17","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111907022883700_B18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/leu.2010.275","article-title":"Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia","volume":"25","author":"Waanders","year":"2011","journal-title":"Leukemia"},{"issue":"25","key":"2019111907022883700_B19","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","article-title":"IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia","volume":"30","author":"Moorman","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111907022883700_B20","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","article-title":"Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111907022883700_B21","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3324\/haematol.2012.075432","article-title":"What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?","volume":"98","author":"Palmi","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"2019111907022883700_B22","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/leu.2015.134","article-title":"IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children\u2019s Leukemia Group study 58951","volume":"29","author":"Clappier","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"2019111907022883700_B23","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"van der Veer","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111907022883700_B24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24625","article-title":"Poor outcomes associated with +der(22)t(9;22) and \u22129\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111907022883700_B25","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2015.03.021","article-title":"Impact of additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"21","author":"Aldoss","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2019111907022883700_B26","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3109\/10428194.2016.1144881","article-title":"Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665","volume":"57","author":"DeBoer","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111907022883700_B27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-016-0270-5","article-title":"Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"9","author":"Xu","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2019111907022883700_B28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/bmt.2014.281","article-title":"Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL","volume":"50","author":"Kim","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2019111907022883700_B29","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/01.cco.0000357476.43164.6b","article-title":"First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults","volume":"21","author":"Ottmann","year":"2009","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"2019111907022883700_B30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/gcc.21961","article-title":"SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3","volume":"51","author":"Nowak","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2019111907022883700_B31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1086\/518809","article-title":"Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of Affymetrix single-nucleotide-polymorphism genotyping microarrays","volume":"81","author":"Yamamoto","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"6","key":"2019111907022883700_B32","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2019111907022883700_B33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111907022883700_B34","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"2019111907022883700_B35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2002-02-0360","article-title":"Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome\/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)","volume":"101","author":"Scheuring","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2019111907022883700_B36","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe Against Cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"2019111907022883700_B37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.seminhematol.2008.09.003","article-title":"Treatment of adult acute lymphoblastic leukemia","volume":"46","author":"G\u00f6kbuget","year":"2009","journal-title":"Semin Hematol"},{"issue":"9881","key":"2019111907022883700_B38","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"2019111907022883700_B39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111907022883700_B40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"issue":"7191","key":"2019111907022883700_B41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"4","key":"2019111907022883700_B42","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood-2007-02-074252","article-title":"Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia","volume":"110","author":"Kreil","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111907022883700_B43","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2009-03-210377","article-title":"SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations [published correction appears in Blood. 2010;115(19):4006]","volume":"115","author":"Nowak","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111907022883700_B44","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111907022883700_B45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111907022883700_B46","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"100","author":"Brissot","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2019111907022883700_B47","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07377.x","article-title":"Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy","volume":"143","author":"Yanada","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111907022883700_B48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3727\/096504013X13786659070271","article-title":"Restoration of INK4a\/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias","volume":"21","author":"Bai","year":"2013","journal-title":"Oncol Res"},{"issue":"18","key":"2019111907022883700_B49","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1101\/gad.1588607","article-title":"Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia","volume":"21","author":"Williams","year":"2007","journal-title":"Genes Dev"},{"issue":"17","key":"2019111907022883700_B50","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1073\/pnas.0602030103","article-title":"Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia","volume":"103","author":"Williams","year":"2006","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/13\/1464\/1404546\/blood796862.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/13\/1464\/1404546\/blood796862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T09:15:24Z","timestamp":1719998124000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/13\/1464\/36631\/Genomic-CDKN2A2B-deletions-in-adult-Ph-ALL-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":50,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,3,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-796862","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,29]]}}}